Rebecca Silbermann

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 653 citations · Full text

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · Journal of Clinical Oncology · 2021 · 238 citations

REPRODUCTIVE COSTS OF HEAT SHOCK PROTEIN IN TRANSGENIC DROSOPHILA MELANOGASTER

Rebecca Silbermann, Marc Tatar · Evolution · 2000 · 169 citations · Full text

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Peter M. Voorhees, Douglas W. Sborov, Jacob P. Laubach et al. · The Lancet Haematology · 2023 · 139 citations

Transplantation-eligible Patients, Hematological Malignancy, Transplantation +11

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · The Lancet Haematology · 2023 · 133 citations · Full text

Hematological Malignancy, Oncology, Final Report +9